Columbia University

Technology Ventures

Latest News

Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care.
See Columbia start-up LuminAID on ABC's Shark Tank!
And now, a three-part, six-hour documentary series based on Siddhartha Mukherjee’s book “The Emperor of All Maladies: A Biography of Cancer” debuts on PBS stations March 30 and continues on March 31 and April 1.
Using advanced DNA sequencing methods, researchers have identified a new gene that is associated with sporadic amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease.
Nanometer-sized “drones” that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis.
One-Blue today announced that Columbia University has joined the One-Blue product licensing program as a licensor.
The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behind its development.
Thomson Reuters Corporation, a mass media and information firm well known for publishing the impact factors of scientific journals, has named 11 CUMC scientists to its list of the world’s most influential scientific minds of 2014.
Andreas Hielscher, professor of biomedical engineering, electrical engineering, and of radiology (physics) is developing a novel technology that could improve diagnosis of this crippling disease and make it easier to monitor patients.
David D. Yao, the Piyasombatkul Family Professor of Industrial Engineering and Operations Research, has been elected to the National Academy of Engineering (NAE), one of the highest professional distinctions awarded to an engineer.